UPDATE 1-FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug
December 06, 2019 at 12:34 PM EST
The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.
